The radiotherapy scheme with extreme hypofractionation has gained space in clinical practice and, therefore, it is necessary to analyze the Brazilian national experience in selected patients with breast cancer, with the aim of evaluating the oncological outcomes and toxicities with the use of this treatment protocol.
Women over 18 years old;
Diagnosis of breast cancer of any molecular subtype;
Undergoing extreme hypofractionated radiotherapy (5 x 5.2Gy) postoperatively;
Treated from December/2019 onward;
The protocol does not provide exclusion criteria.
Latin American Cooperative Oncology Group
Lead sponsor